We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+32.98%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$569M
AUM Growth
+$132M
Cap. Flow
+$70.2M
Cap. Flow %
12.34%
Top 10 Hldgs %
65.09%
Holding
29
New
2
Increased
9
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$47.7M
2
VRNA
Verona Pharma
VRNA
+$14.8M
3
TRVI icon
Trevi Therapeutics
TRVI
+$13.4M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$8.49M
5
VRDN icon
Viridian Therapeutics
VRDN
+$7.65M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$30.5M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$13.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.3M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$8.81M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$6.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
26
Instil Bio
TIL
$49.4M
$3.26M 0.57%
33,695
– –
ALLK
27
DELISTED
Allakos
ALLK
$901K 0.16%
147,189
– –
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-953,396
Closed -$30.5M
CTIC
29
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-2,245,891
Closed -$13.4M
1
2

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return

Fairmount Funds Management's Q3 2022 Portfolio in Review

As of Q3 2022, Fairmount Funds Management held 29 positions worth $569M, up 30% from $437M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Fairmount Funds Management deployed $70.2M of net new capital in Q3 2022, opening 2 new positions and adding to 9 existing holdings. Its largest new stake was Terns Pharmaceuticals: 2,050,000 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was BioCryst Pharmaceuticals, an estimated $10.3M trimmed.

  • Fairmount Funds Management's largest Q3 2022 buy was Terns Pharmaceuticals: 2,050,000 shares worth $12.1M.
  • Fairmount Funds Management added most to Axsome Therapeutics in Q3 2022, an estimated $47.7M increase.
  • Fairmount Funds Management's biggest Q3 2022 reduction was BioCryst Pharmaceuticals, cutting an estimated $10.3M.
  • Fairmount Funds Management fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $30.5M.
  • Fairmount Funds Management's ten largest holdings make up 65% of its $569M portfolio in Q3 2022.
  • Fairmount Funds Management opened 2 new positions and closed 2 in Q3 2022.
  • Fairmount Funds Management's portfolio value rose 30% quarter-over-quarter to $569M.

Based on Fairmount Funds Management's 13F filing for Q3 2022, filed 9 Nov 2022.